Centocor T07 Study
- Date:
- 1991-1996
- Reference:
- SA/KET/A/1/2
- Part of:
- The Kennedy Trust for Rheumatology Research
- Archives and manuscripts
Collection contents
About this work
Description
Comprises papers relating to the open label clinical study C0168T07, "Phase I Study of Chimeric Anti-TNF in Patients with Rheumatoid Arthritis."
The study was sponsored by Centocor and led by the Kennedy Institute for Rheumatology, with investigators Ravinder Maini and Marc Feldmann. The aim of the study was to investigate the safety and the therapeutic effect of a chimeric anti-TNF antibody (code name cA2) in patients with rheumatoid arthritis. Twenty patients were involved in the study which last eight weeks from the first infusion.
See SA/KET/A/2 for further Centocor research collaboration papers.
Publication/Creation
1991-1996
Physical description
3 boxes
Notes
It is noted in the material that some early study files including patient CRFs were sent to Centocor for archiving. Centocor is now a subsidary of Johnson and Johnson.